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Abstract
The P2Y1 receptor (P2Y1R) is a G protein-coupled receptor naturally activated by extracellular
ADP. Its stimulation is an essential requirement of ADP-induced platelet aggregation, thus making
antagonists highly sought compounds for the development of antithrombotic agents. Here, through
a virtual screening campaign based on a pharmacophoric representation of the common
characteristics of known P2Y1R ligands and the putative shape and size of the receptor binding
pocket, we have identified novel antagonist hits of µM affinity derived from a N,N’-bis-arylurea
chemotype. Unlike the vast majority of known P2Y1R antagonists, these drug-like compounds do
not have a nucleotidic scaffold or highly negatively charged phosphate groups. Hence, our
compounds may provide a direction for the development of receptor probes with altered
physicochemical properties.
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1. Introduction
The P2Y receptor (P2YR) family comprises eight subtypes of G protein-coupled receptors
(GPCRs) that are activated by extracellular nucleotides.1 Two subtypes, namely the Gq-
coupled P2Y1R and the Gi-coupled P2Y12R, play a prominent role in platelet aggregation,
since their stimulation by adenosine 5’-diphosphate (ADP) synergistically mediates a
proaggregatory response.2 Since the simultaneous activation of both receptors is required to
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elicit aggregation, antagonists of either subtype act as effective antithrombotic agents. In
particular, antagonists of the P2Y12R, such as liver-activated clopidogrel (Plavix®), are
already widespread clinical tools, while antagonists of the P2Y1R are still under study as an
alternative platform for the development of antiaggregatory drugs.3, 4 With the exception of
a few compounds recently identified by researchers at GlaxoSmithKline5 and Pfizer,6 most
of the known P2Y1R antagonists are based on the structure of adenosine-3',5'-bisphosphate
(A3P5P).7, 8 For example, the selective antagonist (1′R,2′S,4′S,5′S)-4-(2-iodo-6-
methylamino-purin-9-yl)-1-[(phosphato)-methyl]-2-(phosphato)-bicyclo[3.1.0]hexane
(MRS2500), compound 1 (Figure 1), is used widely as a pharmacological probe of the
P2Y1R. It contains a substituted ribose ring moiety, i.e. a methanocarba ring system
(bicyclo[3.1.0]hexane) that is constrained in the P2Y1R-preferring Northern (N)
conformation.9 Notably, compound 1 was shown to be effective in reducing thrombus
formation in vivo and to be more resistant to degradation than related 9-riboside
derivatives.10
Although a crystal structure of the P2Y1R in complex with its ligands has not been solved,
we have extensively studied the molecular recognition at the P2Y1R using a combination of
site-directed mutagenesis, structure-activity relationships (SARs), and molecular modeling
based on the known structure of homologue GPCRs.1, 8, 11–13 In the course of these studies,
we have docked several nucleotide antagonists to the putative ligand binding site of the
P2Y1R. Here, in the quest for P2Y1R antagonists with more drug-like characteristics, we
generated a three-dimensional pharmacophore that reflected the common chemical features
shown by these docked known antagonists. We then performed a pharmacophore-based
virtual screen, which led us to the discovery of novel antagonists derived from non-
nucleotide chemical scaffolds.
2. Results and Discussion
2.1. Construction of the pharmacophore
We have recently published a docking-based QSAR analysis of 53 in-house developed
nucleotide-based antagonists of the P2Y1R.8 On the basis of the docked conformations of
said compounds, here we generated a pharmacophore that reflected their common chemical
characteristics as well as the shape of the putative ligand binding pocket in our P2Y1R
homology model (Figure 1). The number, size and position of the pharmacophoric features
were then adjusted in order to maximize the number of known active compounds able to
pass the pharmacophoric search, leading to a final pharmacophoric query consisting of: a) a
hydrogen-bond donor feature with a radius of 1 Å corresponding to the exocyclic amino
group of the known bisphosphate antagonists, supplemented by a projected feature with a
radius of 1.4 Å - this was necessary to ensure that the H-bond donor feature maintained the
orientation observed in the docked P2Y1antagonists; b) an aromatic or hydrogen bond
acceptor feature with a radius of 2.6 Å, corresponding to the adenine moiety of the known
antagonists; c) six negatively charged or hydrogen-bond acceptor features with a radius of
1.3 Å, corresponding to the phosphate moieties of the known antagonists. The criteria for the
successful passing of the pharmacophore search by a given compound were defined as the
essential matching of the hydrogen-bond donor feature and its projection, and the additional
matching of four of the remaining features. The shape of the P2Y1R binding pocket was
taken into account by adding to the pharmacophore query an excluded volume
corresponding to the residues that line it in our model. These regions were treated as
impenetrable by the ligands. Under these conditions, all the abovementioned 53 known
inhibitors were successfully recognized as ligands through the pharmacophore search.
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A database of approximately 250,000 commercially available compounds was then virtually
screened according to the scheme represented in Figure 2. Prior to the pharmacophore
search, the database was subjected to a descriptor-based filtering to rapidly eliminate the
compounds devoid of the characteristics necessary to match the pharmacophore. In
particular, we eliminated all the compounds endowed with less than one hydrogen bond
donor and less than four hydrogen bond acceptors (or one aromatic ring and three hydrogen
bond acceptors). The resulting filtered database, amounting to about half of the original size,
was then subjected to the pharmacophore search and yielded 362 virtual hits. Aiming at
testing about one hundred compounds, we subjected these virtual hits to a molecular
fingerprint-based clustering, which yielded 51 clusters of molecules with similar structures
and 59 unique singletons. We then selected a total of 110 molecules, i.e. all 59 singletons
and a representative compound for each cluster, choosing the member that in the
pharmacophore search yielded the lowest root mean square deviation (RMSD) with the
query.
2.3. Biological evaluation of the virtual hits and identification of novel ligands
The selected compounds were evaluated for their ability to inhibit the binding of a P2Y1
antagonist radioligand in membranes of human (h) P2Y1R-expressing Sf9 insect cells. The
experimental screening, which was initially conducted studying the inhibition of radioligand
binding by a 20 µM concentration of the tested compounds, yielded the identification of
several novel ligand hits with ≥30% inhibition of [125I]MRS2500 binding (2 – 4).16 Among
them, N,N’-bis-arylurea 2a was found to have an affinity in the low µM range, thus
constituting a very good starting basis for hit optimization. In a subsequent search after the
chemical modification of 2a was initiated, we tested commercially available analogs of
compound 2a and found two structurally related compounds, 2b and 2c, of comparable
affinity. The structure of other tentative library hits (5 – 10) that inhibited only 20% of
radioligand binding are shown in Supporting Information (Table S1).
2.4. Synthesis and biological evaluation of analogs of compound 2a
As mentioned, before the identification of the activity of compounds 2b and 2c we
conducted a preliminary exploration of the SAR of the novel antagonists by synthesizing
analogs of compound 2a. Compound 2a was also resynthesized in order to confirm the
structure provided. In particular, taking advantage of the commercial availability of several
aryl isocyanates, we replaced the dichloro-substituted phenyl ring of 2a with six different
disubstituted analogs. The central phenylsulfonamido or isoxazole rings remained
unmodified. The synthetic route for the preparation of various urea derivatives 2a and 15a-i
is shown in Scheme 1. A coupling reaction between 5-amino-3,4-dimethylisoxazole 11 and
p-nitrobenzenesulfonyl chloride 12 generated the nitro compound 13 in 41% yield. Our
efforts to reduce the nitro group under Pd/C catalyzed hydrogenation reaction conditions
resulted in the nitro reduction along with reduction of the less substituted double bond of the
3,4-dimethylisoxazol-5-yl moiety (results not shown). However, the nitro group was chemo-
selectively reduced using Zn dust in acetic acid to obtain the amine 14 in 69% yield. The
amine 14 was then used as a common intermediate to generate the various urea derivatives
2a and 15a-i, by reacting with the corresponding isocyanates.
The compounds were evaluated for their ability to inhibit P2Y1 antagonist radioligand
binding and to increase intracellular Ca2+ concentration. Selected compounds were found to
inhibit 2-MeSADP-stimulated phospholipase C (PLC) signaling. The binding was measured
in membranes of hP2Y1R-expressing Sf9 insect cells, and the functional assays were
performed in hP2Y1R-expressing 1321N1 human astrocytoma cells. The results, shown in
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Table 2, indicated that several of the in-house synthesized analogs of 2a bind to the P2Y1R
with an affinity in the low µM range, although none of the compounds appeared to be a
better binder than the parent compound. Moreover, the data show that antagonism of
P2Y1R-induced effects was present. In particular, when administered at a concentration of
10 µM, the compounds endowed with higher affinity for the receptor inhibited about 30 %
of the P2Y1R-mediated calcium mobilization induced by the agonist 2-MeSADP. The only
exception appears to be compound 15b that, despite a relatively high binding affinity,
seemed to be a weaker antagonist.
2.5. Analysis of the SAR data
The SAR data indicate that the presence of chlorine substituents at the meta and para
positions of the phenyl ring is crucial for the affinity and the antagonistic activity of
compound 2a. The removal of both chlorine substituents (compound 15a) from compound
2a leads to a complete loss of affinity. Even the sole removal of the chlorine at the para
position (compound 15c) leads to a substantial loss of affinity, which however is partially
regained when a second chlorine atom is reintroduced at the other meta position (compound
15b). The substitution of the chlorine atoms with an electron withdrawing trifluoromethyl
group (compound 15g) is tolerated by the receptor, while their substitution with electron
donating methyl or methoxy groups is not (compounds 15h and 15i). Moreover, the
substitution of the chlorine in para with a fluorine (compound 15d), although somewhat
detrimental, is tolerated. However, the substitution of both chlorines with fluorines leads to a
complete loss of affinity (compound 15e and 15f). Taken together, these data suggest that
the region of the receptor that surrounds the phenyl ring is not inclined to the recognition of
electron rich moieties, thus supporting the structural results of our pharmacophore search
that placed the disubstituted phenyl ring of compound 2a distantly from the negatively
charged phosphate groups of 1. In particular, our pharmacophore search suggests that the
ureic nitrogen of 2a closer the dichlorophenyl ring mimics the exocyclic amino group of 1,
while the 5-sulfonamido-isoxazole moiety of 2a substitutes the two phosphates groups of 1
(Figure 3). According to our published models of the P2Y1R in complex with 1, the
phosphates of this nucleotide antagonist bind to a portion of the binding cavity lined by
cationic residues, which are notoriously electrophilic and fluorophilic residues.14 Compound
2a was more drug-like in its physicochemical properties (cLog p = 3.79) than antagonists
having negatively-charged phosphate groups.
3. Conclusions
In conclusion, our pharmacophore-based virtual screening led to the identification of novel
P2Y1R antagonists endowed with drug-like structures. One of the more promising hits, a
N,N’-bis-phenylurea 2a, from the in silico screen was validated by de novo synthesis and
the preparation of closely related analogues to generate family of non-nucleotide P2Y1
antagonists, some of which displayed affinities and antagonistic potencies in the low µM
range. Thus, these molecules represent good candidates for a follow-up hit optimization
study. Our initial attempts to explore the SAR of the phenyl ring, did not improve the
potency as antagonists, but shed light onto the requirements of ligand recognition.
Moreover, there are additional sites on the molecules, such as the isoxazole ring, that can be
explored, with additional information on other heterocycles from library hit compounds 2b
and 2c.
The novel P2Y1 antagonists identified through this work lack negatively charged phosphate
groups, thus providing more suitable scaffolds for the development of development of
receptor probes with different physicochemical properties from the canonical A3P5P-based
antagonists. However, being devoid of ionized groups, these novel antagonists demonstrate
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that the ionic interactions that the nucleotide antagonists establish with the P2Y1R are not
essential for ligand recognition. Our pharmacophore model suggests that the phosphates of
nucleotide antagonists are replaced by 5-sulfonamido-isoxazole moiety of the novel
antagonists, which most likely establish hydrogen-bonds and cation-aromatic interactions
with the receptor. The confirmation that these substances bind as suggested by the
pharacophore model will depend on the identification of analogues with enhanced affinity.
These molecules may now be subjected to further structural optimization and more
extensive pharmacological characterization in platelet aggregation and other models.
4. Materials and methods
4.1. Molecular Modeling
The molecular modeling study was performed with the Molecular Operating Environment
(MOE), Chemical Computing Group, Inc (www.chemcomp.com). The molecular database
subjected the virtual screening process was the catalogue of compounds commercially
available from Life Chemicals, Inc. (Burlington, ON, Canada, www.lifechemicals.com).
4.1.1. Construction of the pharmacophore—The pharmacophore query was
generated with the "pharmacophore query editor" of MOE. A set of 53 in house-developed
A3P5P-based P2Y1 antagonists8 were loaded into MOE, and an initial query was generated
using the "Consensus" function, according to the PCHD scheme. Only the phosphate groups,
the purine ring, and the exocyclic amino group were taken into account. The resulting query
was then simplified by unifying the aromatic/hydrogen bond acceptor feature relative to the
purine ring and deleting all the projected features. However, we preserved the projected
donor feature relative to the exocyclic amine, in order to ensure its directionality. Moreover,
an excluded volume was added on the basis of all the atoms of the residues lining the
binding pocket in our rhodopsin-based model of the P2Y1R,8 thus accounting for its shape
and size. Specifically, the generation of the excluded volume was based on the following
residues, indicated through their sequence number as well as their GPCR residue index:
L54(1.35), V57(1.38), Y58(1.39), V61(1.42), Y100(2.53), L105(2.57), L108(2.61),
R128(3.29), F131(3.32), H132(3.33), L135(3.36), K196(EL2.44), N197(EL2.45),
I200(EL2.48), T201(EL2.49), Y203(EL2.51), D204(EL2.52), F276(6.51), H277(6.52),
K280(6.55), N283(6.58), Q307(7.36), R310(7.39), G311(7.40), S314(7.43) – for more
information on the GPCR residue index, see Ballesteros and Weinstein15 and Costanzi and
coworkers.1 Finally, we tested the generated pharmacophore query for its ability to correctly
recognize the 53 known antagonists and adjusted the size and the position of the features in
order to ensure the correct recognition of the entire set of the known ligands. For this test,
the 53 known antagonists where sketched from scratch in MOE and subjected to the same
conformational search as the Life Chemicals database, thus recreating the condition used in
the actual pharmacophore search.
4.1.2. Descriptor-based filtering of the database—The number of hydrogen bond
acceptors, hydrogen bond donors and aromatic atoms was calculated for all compounds in
the Life Chemicals database with the "calculate descriptors" function of MOE. To expedite
the screening, we then deleted all the compounds that did not the have the necessary features
to match the pharmacophore query.
4.1.3. Conformational explosion—The resulting filtered Life Chemicals database was
then subjected to a conformational search with the "Conformation Import" function of MOE,
in order to generate for each compound multiple conformers to be evaluated in the
pharmacophore search. The maximum number of conformations per compound was set to
250, and the maximum strain energy for a conformation to be accepted was set to 100 kcal/
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mol. A screenshot with the complete settings is provided in Figure S1 of the Supplementary
Data.
4.1.4. Fingerprint-based clustering—The compounds that passed the pharmacophore
search were clustered on the basis of their molecular similarity according to two different
fingerprints: the MACCS structural keys and the Typed Graph Triangle (TGT) fingerprint.
Both fingerprints are conformation-independent and can be calculated from a two-
dimensional representation of the molecules. The molecular similarity was calculated
according to the Tanimoto coefficient, and the clustering was done setting the threshold for
similarity and overlap to 80% for the MACCS and 88% for the TGT fingerprints. From the
clusters independently calculated with the two fingerprints, a consensus cluster was then
generated with a union operation via an ad hoc written script.
4.2. Chemical synthesis
The synthetic procedures for intermediates are described here, while analytical and
spectroscopic data for each compound tested biologically are given below. Compounds
subjected to biological testing were of >95% purity. For structural confirmation, 1H NMR
spectra were recorded at 300 Mz. Chemical shifts are reported in parts per million (ppm)
relative to deuterated solvent as the internal standard. ESI-High resolution mass
spectroscopic measurements were performed on a proteomics optimized Q-TOF-2
(Micromass-Waters) using external calibration with polyalanine. cLog p was calculated
using ChemBioDraw Ultra v. 12.03 (PerkinElmer, Boston, MA).
N-(3,4-Dimethylisoxazol-5-yl)-4-nitrobenzenesulfonamide (13)—5-Amino-3,4-
dimethylisoxazole 11 (0.20 g, 1.78 mmol) and p-nitrobenzenesulfonyl chloride 12 (0.39 g,
1.78 mmol) were dissolved in anhydrous CH2Cl2 (20 mL). Et3N (0.75 mL, 5.36 mmol) and
N,N-dimethylaminopyridine (44 mg, 0.36 mmol) were then added. After stirring the reaction
mixture for 42 h, it was diluted with EtOAc (50 mL) and washed with sat. aq. NaHCO3 (1 ×
20 mL) and sat. aq. NaCl (1 × 20 mL). The aqueous phase was back extracted with EtOAc
(3 × 20 mL), and the combined organic phases were evaporated to dryness. The resulting
residue was purified by silica gel column chromatography (0–10% MeOH in EtOAc, v/v) to
afford compound 13 (0.22 g, 41%) as a solid.
4.2.1. 4-Amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide (14)—Nitro
compound 13 (0.71 g, 2.40 mmol) was dissolved in a mixture of AcOH:CH3CN (20 mL,
1:1, v/v) and cooled to 0 °C. Zn powder (1.5 g) was added in small portions over a period of
10 min. After stirring the reaction for 3 h at rt, reaction mixture was filtered off and filtrate
was evaporated to dryness. The resulting residue was purified by silica gel column
chromatography (0–10% MeOH in EtOAc, v/v) to afford amine 14 (0.65 g, 69%) as a solid.
4.2.2. General experimental procedure for compounds 2a and 15a-i
Method A: Amine 14 (25 mg, 0.094 mmol) was coevaporated with anhydrous toluene (3 ×
3 mL) and dissolved in anhydrous THF (2 mL). Diisopropylethylamine (66 µL, 0.38 mmol)
and the corresponding isocyanate (0.140 mmol) were added. After stirring for 2 h at 70 °C,
the reaction mixture was diluted with EtOAc (25 mL) and washed with saturated aq. NaCl
(1 × 15 mL). The aqueous phase was back extracted with EtOAc (3 × 20 mL), and the
combined organic phases were evaporated to dryness. The resulting residue was purified by
silica gel column chromatography (0–10% MeOH in EtOAc, v/v) to afford target
compounds 2a and 15b, 15d-f, and 15h-i, as solid materials.
Method B: Amine 14 (15 mg, 0.056 mmol) was coevaporated with anhydrous toluene (3 ×
3 mL) and dissolved in anhydrous THF (2 mL). Diisoproylethylamine (40 µL, 0.224 mmol)
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and corresponding isocyanate (0.224 mmol) were added. After stirring for 16 h at room
temperature, the reaction mixture was evaporated to dryness. The resulting residue was
purified by silica gel column chromatography (0–6% MeOH in EtOAc, v/v) to afford target
compounds 15a, 15c and 15g as solid materials.
4.2.2.1. 4-(3-(3,4-Dichlorophenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (2a): Rf = 0.5 (10% MeOH in EtOAc, v/v); ESI-HRMS m/z
455.0331 ([M + H]+, C18H16N4O4SCl2·H+: Calcd. 455.0348); 1H NMR (CD3OD) δ 7.81 (d,
J = 2.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.42 (d, J = 8.8 Hz, 1H),
7.31 (dd, J = 2.8, 8.8 Hz, 1H), 2.14 (s, 3H), 1.78 (s, 3H).
4.2.2.2. N-(3,4-Dimethylisoxazol-5-yl)-4-nitrobenzenesulfonamide (13): Rf = 0.2 (10%
MeOH in EtOAc, v/v); ESI-HRMS m/z 298.0492 ([M + H]+, C11H11N3O5S·H+: Calcd.
298.0498); 1H NMR (CDCl3) δ 8.37 (d, J = 8.8 Hz, 2H), 8.01 (d, J = 8.8 Hz, 2H), 2.22 (s,
3H), 1.98 (s, 3H), 1.57 (s, 1H).
4.2.2.3. 4-Amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide (14): Rf = 0.4 (7%
MeOH in EtOAc, v/v); ESI-HRMS m/z 268.0767 ([M + H]+, C11H13N3O3S·H+: Calcd.
268.0756); 1H NMR (CDCl3) δ 7.56 (d, J = 8.8 Hz, 2H), 6.64 (d, J = 8.8 Hz, 2H), 4.19 (s,
2H), 2.18 (s, 3H), 1.91 (s, 3H), 1.59 (s, 1H).
4.2.2.3.4. N-(3,4-Dimethylisoxazol-5-yl)-4-(3-phenylureido)benzenesulfonamide (15a):
Rf = 0.2 (5% MeOH in CH2Cl2, v/v); ESI-HRMS m/z 387.1118 ([M + H]+,
C18H18N4O4S·H+: Calcd. 387.1127); 1H NMR (CD3OD) δ, 7.72 (d, J = 9.1 Hz, 2H), 7.64
(d, J = 9.1 Hz, 2H), 7.40–7.48 (m, 2H), 7.27–7.34 (m, 2H), 7.02–7.07 (m, 1H), 2.16 (s, 3H),
1.79 (s, 3H).
4.2.2.3.5. 4-(3-(3,5-Dichlorophenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (15b): Rf = 0.2 (5% MeOH in EtOAc, v/v); ESI-HRMS m/z
455.0348 ([M + H]+, C18H16N4O4SCl2·H+: Calcd. 455.0348); 1H NMR (CD3OD) δ 7.93 (d,
J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 1.7 Hz, 2H), 7.06–7.08 (m, 1H), 2.07
(s, 3H), 1.19 (s, 3H).
4.2.2.3.6. 4-(3-(3-Chlorophenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (15c): Rf = 0.3 (5% MeOH in CH2Cl2, v/v); ESI-HRMS m/z
421.0725 ([M + H]+, C18H17N4O4SCl·H+: Calcd. 421.0737); 1H NMR (CD3OD) δ, 7.74 (d,
J = 8.1 Hz, 2H), 7.60–7.69 (m, 3H), 7.23–7.32 (m, 2H), 7.02–7.07 (m, 1H), 2.16 (s, 3H),
1.79 (s, 3H).
4.2.2.3.7. 4-(3-(3-Chloro-4-fluorophenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (15d): Rf = 0.2 (5% MeOH in EtOAc, v/v); ESI-HRMS m/z
439.0641 ([M + H]+, C18H16N4O4FClS·H+: Calcd. 439.0643); 1H NMR (CD3OD) δ 7.70–
7.80 (m, 3H), 7.65 (d, J = 8.8 Hz, 2H), 7.20–7.30 (m, 1H), 7.05–7.15 (m, 1H), 2.13 (s, 3H),
1.79 (s, 3H).
4.2.2.3.8. 4-(3-(3,4-Difluorophenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (15e): Rf = 0.2 (7% MeOH in EtOAc, v/v); ESI-HRMS m/z
423.0924 ([M + H]+, C18H16N4O4SF2·H+: Calcd. 423.0939); 1H NMR (CD3OD) δ 7.76 (d,
J = 8.8 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 7.18–7.21 (m, 2H), 7.09–7.12 (m, 1H), 2.16 (s,
3H), 1.77 (s, 3H).
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yl)benzenesulfonamide (15f): Rf = 0.2 (5% MeOH in EtOAc, v/v); ESI-HRMS m/z
423.0934 ([M + H]+, C18H16N4O4F2S·H+: Calcd. 423.0939); 1H NMR (CD3OD) δ 7.75 (d,
J = 8.8 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 7.14 (d, J = 8.2 Hz, 2H), 6.54–6.61 (m, 1H), 2.13
(s, 3H), 1.78 (s, 3H).
4.2.2.3.10. N-(3,4-Dimethylisoxazol-5-yl)-4-(3-(4-(trifluoromethyl)phenyl)ureido)-
benzenesulfonamide (15g): Rf = 0.2 (5% MeOH in CH2Cl2, v/v); ESI-HRMS m/z
387.1118 ([M + H]+, C19H17N4O4S·H+: Calcd. 387.1127); 1H NMR (CD3OD) δ, 7.73 (d, J
= 8.6 Hz, 2H), 7.60–7.68 (m, 4H), 7.58 (d, J = 8.7 Hz, 2H), 2.15 (s, 3H), 1.79 (s, 3H).
4.2.2.3.11. 4-(3-(3,4-Dimethoxyphenyl)ureido)-N-(3,4-dimethylisoxazol-5-
yl)benzenesulfonamide (15h): Rf = 0.2 (5% MeOH in EtOAc, v/v); ESI-HRMS m/z
447.1343 ([M + H]+, C20H23N4O6S·H+: Calcd. 447.1338); 1H NMR (CD3OD) δ 7.72 (d, J =
8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 2.2 Hz, 1H), 6.83–6.92 (m, 2H), 3.84 (s,
3H), 3.81 (s, 3H), 2.13 (s, 3H), 1.77 (s, 3H).
4.2.2.3.12. N-(3,4-Dimethylisoxazol-5-yl)-4-(3-(3,4-
dimethylphenyl)ureido)benzenesulfonamide (15i): Rf = 0.2 (5% MeOH in EtOAc, v/v);
ESI-HRMS m/z 415.1447([M + H]+, C20H22N4O4S·H+: Calcd. 415.1440); 1H NMR
(CD3OD) δ 7.70 (d, J = 8.8 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.11–7.21 (m, 2H), 7.04 (d, J
= 8.2 Hz, 1H), 2.24 (s, 3H), 2.21 (s, 3H), 2.14 (s, 3H), 1.77 (s, 3H).
4.3. Pharmacological evaluation
4.3.1. Radioligand binding assay—Binding of [125I]MRS2500, a potent, selective,
antagonist of the P2Y1R was performed as reported elsewhere.16, 17 2-MeSADP was
purchased from Sigma (St. Louis, MO). Myo-[3H]inositol (20 Ci/mmol) was obtained from
American Radiolabeled Chemicals (St. Louis, MO).
4.3.2. Assay of inositol phosphates—Selected compounds were examined for
inhibition of P2Y1R-promoted stimulation of inositol phosphate formation measured at the
hP2Y1R stably expressed in 1321N1 human astrocytoma cells as previously
described.8, 18, 19 The IC50 values were averaged from 3 independently determined
concentration-effect curves for each compound. Briefly, cells plated in 24-well dishes were
labeled in inositol-free medium (DMEM; Gibco, Gaithersburg, MD) containing 1.0 µCi of
2-[3H]myo-inositol (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St. Louis, MO)
for 18–24 h in a humidified atmosphere of 95% air / 5% CO2 at 37°C. PLC activity was
measured the following day by quantitating [3H]inositol phosphate accumulation after a 10
min incubation at 37°C in the presence of 10 mM LiCl. Total [3H]inositol phosphates were
quantified by anion exchange chromatography as previously described.
4.3.3. Calcium mobilization assay—Changes in intracellular calcium ion concentration
induced by the hP2Y1R stably expressed in 1321N1 human astrocytoma cells were
measured as reported.20 Specifically, 1321N1 human astrocytoma cells stably expressing the
hP2Y1R were cultured in DMEM (JRH Biosciences, Inc., Lenexa, KS) supplemented with
5% fetal bovine serum, 100 units penicillin mL−1, 100 µg streptomycin mL−1, 2 µmol
glutamine mL−1, and 800 µg geneticin mL−1. For the assay, cells were grown overnight in
100 µL of media in 96-well flat-bottom plates at 37 °C at 5% CO2 or until approximately
60–80% confluency. The calcium 4 assay kit (Molecular Devices, Sunnyvale, CA) was used
as directed without washing of the cells. Cells were loaded with 30 µL of dye to each well
and incubated for 1 h at room temperature. All the tested compounds were diluted to the
appropriate concentration in Hank’s buffer. Dose-response curves for the agonist 2-
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MeSADP were obtained treating the cells with six different concentration of the compound
in the range between (10−9 M to 10−5 M). For the antagonist studies, the same dose-response
curves were registered in the presence of the newly identified P2Y1 ligands, pretreating the
cells for 20 min at room temperature with a 10 µM concentration of each candidate
antagonist before application of the agonist 2-MeSADP. Samples were run in triplicates
using a Molecular Devices FLIPRTETRA at room temperature. Cell fluorescence (excitation
= 485 nm, emission = 525 nm) was monitored following exposure to the compound.
Increases in intracellular calcium are reported as the maximum fluorescence value after
exposure minus the basal fluorescence value before exposure.
Binding and functional parameters were estimated using GraphPAD Prism software
(GraphPAD, San Diego, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representation of the pharmacophore at the base of the virtual screening, embedded within
the homology model of the P2Y1R: the hydrogen bond donor feature is in light purple; its
projection is in dark purple; the aromatic or hydrogen bond acceptor feature is in indigo; the
negatively charged or hydrogen bond acceptor features are in pink. The ribbon
representation of the backbone of the receptor is colored with a continuum spectrum going
from red at the N-terminus to purple at the C-terminus, with TM1 in orange, TM2 in yellow/
green, TM3 in green, TM4 in blue/green, TM5 in cyan, TM6 in blue and TM7 in purple.
The high affinity antagonist MRS2500 (1) appears in the figure, with its carbon atoms in
yellow, while a schematic 2D representation is shown in the lower left inset. Three cationic
residues that, according to experimental evidence, are fundamental for ligand recognition are
also shown, with their carbon atoms in grey.
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Schematic representation of the virtual screening process.
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Superimposition of MRS2500 (1) and compound 2, as resulting from the pharmacophore
search. MRS2500 is shown in ball and stick representation, with the carbon atoms colored in
green. Compound 2 is shown in stick representation, with the carbon atoms colored in grey.
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Table 1
In vitro pharmacological data for compounds selected through an in silico screen (Life Chemicals code
shown) for inhibition of radioligand binding at the hP2Y1R.




2a, F3099-0019 13 ± 3
2b, F0348-3162 6
2c, F1766-0041 10
3, F2019-1559 40 %b
4, F1795-0008 30 %b
a
Assays were with membranes from Sf9 insect cells expressing the hP2Y1R and performed with a radioligand ([125I]MRS2500) concentration of
approximately 0.2 nM.
b
Percent inhibition of specific binding of [125I]MRS2500 by a 20 µM concentration of test compound.
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Table 2
In vitro pharmacological data for the synthesized analogs of compound 2a at the hP2Y1R in binding,
determined as in Table 1, and in the antagonism increase of intracellular calcium ion concentration induced by
30 nM 2-MeSADP in 1321N1 astrocytoma cells expressing the hP2Y1R.





2a (F3099-0019) 13 ± 3 36.8 ± 2.2a
15 a NE < 5
15b 27 ± 10 17.6 ± 1
15c ≥ 100 21.7 ± 3.5
15d 42 ± 15 31.3 ± 2.5
15e NE 11.3 ± 2.3
15f ≥ 100 10.2 ± 2.6
15g 45 ± 8 32.7 ± 3.7
15h NE 9.1 ± 0.4
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15i NE 9.4 ± 0.2b
a
IC50 in the IP Assay: 0.14 ± 0.04 µM;
b
IC50 in the IP Assay: 0.13 ± 0.01 µM; NE – less than 10% inhibition at 20 µM.
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